Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

Coffee and other natural bitters can help the liver work better. Supplements, such as digestive enzymes, lecithin, berberine, ...

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille ...

AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual ...

Bilirubin, the byproduct of hemoprotein breakdown, particularly hemoglobin, is a critical marker in diagnosing, prognosing, ...

Bilirubin, the byproduct of hemoprotein breakdown, particularly hemoglobin, is a critical marker in diagnosing, prognosing, and managing liver ...

Bilirubin, the primary breakdown product of hemoproteins, particularly hemoglobin, plays a key role in the diagnosis, prognosis, and monitoring of liver diseases. In acute liver diseases, such as ...

Peking University-led researchers have modified an existing treatment for liver disease that does not cause itchiness, a ...

Mirum Pharmaceuticals, Inc. today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November ...

Addressing the challenge of cholestatic itch, the scientific community has been pursuing innovative solutions. Recently, researchers from Peking University, led by Professor Lei Xiaoguang, in ...

She was diagnosed with primary biliary cholangitis (PBC) at the age of 50 - a rare, incurable liver disease in which the bile ducts in the organ become inflamed. It can cause painful joints and ...

PBC is a lifelong condition that can worsen over time if inadequately treated, causing liver failure, leading to liver transplant and in rare cases, premature death. Despite the critical impact of the ...